GPR174

Summary

GPR174 (G protein-coupled receptor 174, HGNC:30245) is a protein-coding gene on chromosome Xq21.1, encoding Probable G-protein coupled receptor 174 (Q9BXC1). G-protein-coupled receptor of lysophosphatidylserine (LysoPS) that plays different roles in immune response.

This gene encodes a protein belonging to the G protein-coupled receptor superfamily. These proteins are characterized by the presence of seven alpha-helical transmembrane domains, and they activate or interact with various endogenous or exogenous ligands, including neurotransmitters, hormones, and odorant and taste substances. This family member is classified as an orphan receptor because the cognate ligand has not been identified.

Source: NCBI Gene 84636 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 39 total
• Druggable target: yes
• MANE Select transcript: NM_032553

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30245
Approved symbol	GPR174
Name	G protein-coupled receptor 174
Location	Xq21.1
Locus type	gene with protein product
Status	Approved
Aliases	FKSG79, LPS3
Ensembl gene	ENSG00000147138
Ensembl biotype	protein_coding
OMIM	300903
Entrez	84636

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000645147, ENST00000871945

RefSeq mRNA: 1 — MANE Select: NM_032553 NM_032553

CCDS: CCDS14443

Canonical transcript exons

ENST00000645147 — 3 exons

Exon	Start	End
ENSE00003826852	79144688	79145217
ENSE00003827115	79156822	79156918
ENSE00003827781	79170452	79175318

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 88.24.

FANTOM5 (CAGE): breadth broad, TPM avg 10.4909 / max 563.0730, expressed in 286 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196794	10.3964	286
196795	0.0945	54

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
thymus	UBERON:0002370	88.24	gold quality
ileal mucosa	UBERON:0000331	83.30	gold quality
lymph node	UBERON:0000029	83.15	gold quality
granulocyte	CL:0000094	82.07	gold quality
vermiform appendix	UBERON:0001154	77.67	gold quality
epithelium of nasopharynx	UBERON:0001951	75.85	gold quality
colonic epithelium	UBERON:0000397	75.16	gold quality
spleen	UBERON:0002106	73.98	gold quality
superficial temporal artery	UBERON:0001614	71.70	silver quality
blood	UBERON:0000178	71.39	gold quality
caecum	UBERON:0001153	70.67	gold quality
bone marrow cell	CL:0002092	70.10	silver quality
tonsil	UBERON:0002372	69.74	gold quality
jejunal mucosa	UBERON:0000399	68.92	gold quality
bone marrow	UBERON:0002371	68.45	gold quality
leukocyte	CL:0000738	67.09	gold quality
rectum	UBERON:0001052	66.11	gold quality
monocyte	CL:0000576	65.36	gold quality
trabecular bone tissue	UBERON:0002483	64.76	gold quality
tibialis anterior	UBERON:0001385	64.05	silver quality
small intestine Peyer’s patch	UBERON:0003454	63.19	gold quality
duodenum	UBERON:0002114	63.13	gold quality
mucosa of sigmoid colon	UBERON:0004993	63.04	gold quality
gall bladder	UBERON:0002110	62.99	gold quality
small intestine	UBERON:0002108	62.71	gold quality
pancreatic ductal cell	CL:0002079	61.87	silver quality
mucosa of transverse colon	UBERON:0004991	61.16	gold quality
palpebral conjunctiva	UBERON:0001812	61.07	gold quality
colonic mucosa	UBERON:0000317	60.66	gold quality
jejunum	UBERON:0002115	59.01	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.06

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting GPR174, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-505-3P	99.19	69.71	896
HSA-MIR-11399	98.71	65.69	869
HSA-MIR-4274	98.59	66.10	630
HSA-MIR-4468	98.01	66.85	1187
HSA-MIR-146B-3P	97.83	65.29	782
HSA-MIR-6893-3P	97.79	64.91	1238
HSA-MIR-2278	97.30	66.19	1130
HSA-MIR-370-3P	97.09	64.92	1221
HSA-MIR-503-3P	92.89	66.09	537

Literature-anchored findings (GeneRIF, showing 10)

• These results suggested that GPR174 was a putative LysoPS receptor conjugating with Galpha(s), and its expression induced morphological changes in CHO cells by constitutively activating adenylyl cycles accompanied with cell conjunctions and delay of proliferation. (PMID:23178570)
• The finding of an X-linked risk locus for Graves’ disease expands our understanding of the role of the X chromosome in disease susceptibility. (PMID:23667180)
• this study provides the first replication in a Caucasian population of the association between Graves’ disease and the GPR174 rs3827440 single nucleotide polymorphism originally reported among Chinese. (PMID:24289805)
• We have demonstrated a significant association of this X chromosome-encoded immunoreceptor with autoimmune Addison’s disease for the first time. (PMID:25295623)
• Alteration of gene expression profiling including GPR174 and GNG2 is associated with vasovagal syncope. (PMID:25367286)
• Studied association of and RNASET2, GPR174, and PTPN22 gene polymorphisms and liver damage(LD) due to Graves’ disease (GD) hyperthyroidism. Found GPR174 rs3827440, PTPN22 rs3789604, and RNASET2 rs9355610 were significantly associated with altered GD-derived LD risk. (PMID:28568286)
• GPR174 and ITM2A Gene Polymorphisms rs3827440 and rs5912838 on the X chromosome in Korean Children with Autoimmune Thyroid Disease. (PMID:32727090)
• GPR174 mRNA Acts as a Novel Prognostic Biomarker for Patients With Sepsis via Regulating the Inflammatory Response. (PMID:35173706)
• Gpr174 Knockout Alleviates DSS-Induced Colitis via Regulating the Immune Function of Dendritic Cells. (PMID:35669778)
• Structural basis for ligand recognition and signaling of the lysophosphatidylserine receptors GPR34 and GPR174. (PMID:38048360)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gpr174	ENSMUSG00000073008
rattus_norvegicus	Gpr174	ENSRNOG00000032970

Paralogs (7): GPR146 (ENSG00000164849), GPR183 (ENSG00000169508), GPR151 (ENSG00000173250), RXFP3 (ENSG00000182631), GPR132 (ENSG00000183484), GPR141 (ENSG00000187037), P2RY11 (ENSG00000244165)

Protein

Protein identifiers

Probable G-protein coupled receptor 174 — Q9BXC1 (reviewed: Q9BXC1)

All UniProt accessions (1): Q9BXC1

UniProt curated annotations — full annotation on UniProt →

Function. G-protein-coupled receptor of lysophosphatidylserine (LysoPS) that plays different roles in immune response. Plays a negative role in regulatory T-cell accumulation and homeostasis. Under inflammatory conditions where LysoPS production increases, contributes to the down-regulation of regulatory T-cell activity to favor effector response. Mediates the suppression of IL-2 production in activated T-lymphocytes leading to inhibition of growth, proliferation and differentiation of T-cells. Mechanistically, acts via G(s)-containing heterotrimeric G proteins to trigger elevated cyclic AMP levels and protein kinase A/PKA activity, which may in turn act to antagonize proximal TCR signaling. Plays an important role in the initial period of sepsis through the regulation of macrophage polarization and pro- and anti-inflammatory cytokine secretions. Upon testosterone treatment, acts as a receptor for CCL21 and subsequently triggers through G(q)-alpha and G(12)/G(13) proteins a calcium flux leading to chemotactic effects on activated B-cells. Signals via GNA13 and PKA to promote CD86 up-regulation by follicular B-cells.

Subunit / interactions. Interacts with GNA13. Interacts with CCL21.

Subcellular location. Cell membrane.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_115942* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR047836	GPR174_7tmA	Domain

Pfam: PF00001

UniProt features (41 total): helix 12, topological domain 8, transmembrane region 7, mutagenesis site 4, strand 4, glycosylation site 2, chain 1, disulfide bond 1, sequence variant 1, turn 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
9XXT	ELECTRON MICROSCOPY	2
7XV3	ELECTRON MICROSCOPY	2.76
8KH5	ELECTRON MICROSCOPY	2.83
8IZB	ELECTRON MICROSCOPY	3.06
20YC	ELECTRON MICROSCOPY	3.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BXC1-F1	84.18	0.53

Antibody-complex structures (SAbDab): 3 — 7XV3, 8IZB, 8KH5

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 91–168

Glycosylation sites (2): 4, 164

Mutagenesis-validated functional residues (4):

Position	Phenotype
22	substantially reduced receptor activity.
75	substantially reduced receptor activity.
98	substantially reduced receptor activity.
156	substantially reduced receptor activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 104 (showing top): FREAC2_01, BENPORATH_ES_WITH_H3K27ME3, GOBP_T_CELL_HOMEOSTASIS, GOBP_LYMPHOCYTE_HOMEOSTASIS, FOXO1_01, CAGCTG_AP4_Q5, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_CYTOKINE_PRODUCTION, TGANTCA_AP1_C, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, GOBP_NEGATIVE_REGULATION_OF_CYTOKINE_PRODUCTION, FOXO4_02, GOBP_LEUKOCYTE_HOMEOSTASIS, GOBP_NEGATIVE_REGULATION_OF_INTERLEUKIN_2_PRODUCTION, GOBP_HOMEOSTATIC_PROCESS

GO Biological Process (5): G protein-coupled receptor signaling pathway (GO:0007186), negative regulation of interleukin-2 production (GO:0032703), T cell homeostasis (GO:0043029), signal transduction (GO:0007165), adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189)

GO Molecular Function (2): G protein-coupled receptor activity (GO:0004930), bioactive lipid receptor activity (GO:0045125)

GO Cellular Component (3): plasma membrane (GO:0005886), centriolar satellite (GO:0034451), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor activity	2
cellular anatomical structure	2
signal transduction	1
negative regulation of cytokine production	1
interleukin-2 production	1
regulation of interleukin-2 production	1
lymphocyte homeostasis	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase activator activity	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
membrane	1
cell periphery	1
centrosome	1

Protein interactions and networks

STRING

754 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR174	PLA1A	Q53H76	511
GPR174	LPAR2	Q9HBW0	463
GPR174	CCL21	O00585	461
GPR174	ARHGAP15	Q53QZ3	438
GPR174	ABHD12	Q8N2K0	437
GPR174	POU2AF1	Q16633	429
GPR174	CR2	P20023	426
GPR174	BTLA	Q7Z6A9	423
GPR174	ITM2A	O43736	418
GPR174	ABHD16A	O95870	418
GPR174	CD69	Q07108	415
GPR174	GPR22	Q99680	411
GPR174	TMEM89	A2RUT3	399
GPR174	CD22	P20273	382
GPR174	ARMCX5	Q6P1M9	372

IntAct

7 interactions, top by confidence:

A	B	Type	Score
RAMP1	GPR174	psi-mi:“MI:0915”(physical association)	0.400
RAMP2	GPR174	psi-mi:“MI:0915”(physical association)	0.400
GPR174	RAMP2	psi-mi:“MI:0915”(physical association)	0.400
GPR174	RAMP3	psi-mi:“MI:0915”(physical association)	0.400
RAMP3	GPR174	psi-mi:“MI:0915”(physical association)	0.400
	GPR174	psi-mi:“MI:0915”(physical association)	0.000

ESM2 similar proteins: A1A5S3, A5PLE7, B0UXR0, B5X337, F5HDK1, F5HF62, F8VQN3, O00421, O18982, O97663, P09703, P32249, P35351, P35374, P46002, P49685, P50052, P51676, P56412, P69332, P69333, Q01035, Q0II78, Q0VDU3, Q14330, Q1RMI1, Q28929, Q3T0E9, Q3U507, Q4R613, Q6IYF9, Q75ZH0, Q83207, Q89609, Q8BZR0, Q8IYL9, Q8K1Z6, Q95N03, Q96P67, Q98146

Diamond homologs: A5PLE7, B0UXR0, B5X337, D4A7K7, F1MV99, O08858, O35210, O35811, O77590, O88634, P11613, P21556, P25025, P25095, P25104, P25106, P26824, P29089, P29754, P29755, P30555, P30556, P30937, P30938, P31391, P32249, P32250, P32300, P33396, P33535, P34976, P35346, P35366, P35372, P35373, P35383, P41143, P41231, P41232, P42866

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
GPR174	“up-regulates activity”	GNAS	binding
GPR174	“up-regulates activity”	GNAL	binding
GPR174	“up-regulates activity”	GNA13	binding
“lysophosphatidylserine 14:0(1-)”	“up-regulates activity”	GPR174	“chemical activation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	28
Likely benign	6
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

311 predictions. Top by Δscore:

Variant	Effect	Δscore
X:79171648:A:G	donor_gain	0.7100
X:79171718:G:T	donor_gain	0.6100
X:79171714:CAGGG:C	donor_gain	0.5900
X:79171716:GGG:G	donor_gain	0.5800
X:79171717:GGG:G	donor_gain	0.5800
X:79171227:CTG:C	acceptor_gain	0.5700
X:79171712:TGCAG:T	donor_gain	0.5700
X:79171713:GCAGG:G	donor_gain	0.5700
X:79171852:GTCT:G	acceptor_gain	0.5700
X:79171574:C:T	donor_gain	0.5600
X:79171621:C:G	acceptor_gain	0.5600
X:79171851:A:AG	acceptor_gain	0.5600
X:79171852:G:GG	acceptor_gain	0.5600
X:79171228:TG:T	acceptor_gain	0.5100
X:79171753:GTTTT:G	acceptor_gain	0.5100
X:79171225:CACTG:C	acceptor_gain	0.5000
X:79171226:ACTGA:A	acceptor_gain	0.5000
X:79171229:G:GC	acceptor_gain	0.5000
X:79171620:ACCT:A	acceptor_gain	0.5000
X:79171752:A:AG	acceptor_gain	0.5000
X:79171753:G:GG	acceptor_gain	0.5000
X:79171896:AAT:A	acceptor_gain	0.5000
X:79171834:T:TA	acceptor_gain	0.4900
X:79171960:CCTTT:C	donor_gain	0.4900
X:79171686:A:T	donor_gain	0.4800
X:79171807:GAAGG:G	donor_gain	0.4800
X:79171851:AGTCT:A	acceptor_gain	0.4800
X:79171852:GTCTG:G	acceptor_gain	0.4800
X:79171961:CTTTG:C	donor_loss	0.4800
X:79171964:TGT:T	donor_loss	0.4800

AlphaMissense

2198 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:79171259:G:C	W84C	0.999
X:79171259:G:T	W84C	0.999
X:79171431:T:A	W142R	0.999
X:79171431:T:C	W142R	0.999
X:79171201:A:C	D65A	0.998
X:79171202:C:A	D65E	0.998
X:79171202:C:G	D65E	0.998
X:79171734:T:C	F243L	0.998
X:79171736:T:A	F243L	0.998
X:79171736:T:G	F243L	0.998
X:79171104:G:C	G33R	0.997
X:79171105:G:A	G33D	0.997
X:79171118:T:A	N37K	0.997
X:79171118:T:G	N37K	0.997
X:79171200:G:C	D65H	0.997
X:79171201:A:G	D65G	0.997
X:79171201:A:T	D65V	0.997
X:79171257:T:A	W84R	0.997
X:79171257:T:C	W84R	0.997
X:79171344:A:C	S113R	0.997
X:79171346:T:A	S113R	0.997
X:79171346:T:G	S113R	0.997
X:79171752:A:C	S249R	0.997
X:79171754:T:A	S249R	0.997
X:79171754:T:G	S249R	0.997
X:79171851:A:C	S282R	0.997
X:79171853:T:A	S282R	0.997
X:79171853:T:G	S282R	0.997
X:79171320:A:C	S105R	0.996
X:79171322:C:A	S105R	0.996

dbSNP variants (sampled 300 via entrez): RS1000143245 (X:79164442 T>A), RS1000597444 (X:79149167 A>T), RS1000603080 (X:79158015 T>C), RS1000924977 (X:79174269 T>G), RS1000942238 (X:79145413 G>A), RS1000949253 (X:79157732 G>A), RS1001267173 (X:79145526 G>C,T), RS1001275188 (X:79154245 G>A,T), RS1001539190 (X:79162363 G>A,C), RS1001546385 (X:79166107 T>C), RS1001592507 (X:79145823 G>A,T), RS1001595903 (X:79170243 T>G), RS1001690134 (X:79149594 G>A,C), RS1002023202 (X:79169923 T>C), RS1002032046 (X:79147068 G>T)

Disease associations

OMIM: gene MIM:300903 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001984_4	Graves’ disease	2.000000e-33

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3562167 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with emerging pharmacology

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
lysophosphatidylserine	Full agonist	7.1	pEC50

ChEMBL bioactivities

136 potent at pChembl≥5 of 138 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.75	EC50	18	nM	CHEMBL3577172
7.74	EC50	18.2	nM	CHEMBL3577172
7.70	IC50	20	nM	CHEMBL4851095
7.60	EC50	25	nM	CHEMBL3577175
7.60	EC50	25.12	nM	CHEMBL3577175
7.51	EC50	31	nM	CHEMBL3577265
7.51	EC50	30.9	nM	CHEMBL3577265
7.48	EC50	33	nM	CHEMBL3577174
7.48	EC50	33.11	nM	CHEMBL3577174
7.40	EC50	40	nM	CHEMBL3577263
7.40	EC50	39.81	nM	CHEMBL3577263
7.36	EC50	44	nM	CHEMBL3577171
7.36	EC50	43.65	nM	CHEMBL3577171
7.20	EC50	63	nM	CHEMBL3577156
7.20	EC50	63.1	nM	CHEMBL3577156
7.12	EC50	76	nM	CHEMBL3577173
7.12	EC50	75.86	nM	CHEMBL3577173
7.09	EC50	82	nM	CHEMBL3577168
7.09	EC50	81.28	nM	CHEMBL3577168
7.07	EC50	86	nM	CHEMBL3577176
7.07	EC50	85.11	nM	CHEMBL3577176
7.00	IC50	100	nM	CHEMBL4863268
7.00	IC50	100	nM	CHEMBL4868780
6.82	IC50	150	nM	CHEMBL4864992
6.70	EC50	200	nM	CHEMBL4851095
6.54	EC50	290	nM	CHEMBL3577144
6.54	EC50	288.4	nM	CHEMBL3577144
6.52	EC50	300	nM	CHEMBL4855006
6.52	EC50	300	nM	CHEMBL4867113
6.52	EC50	300	nM	CHEMBL4863268
6.52	EC50	300	nM	CHEMBL4850132
6.40	EC50	400	nM	CHEMBL4867113
6.40	EC50	400	nM	CHEMBL4853607
6.40	EC50	400	nM	CHEMBL4847967
6.40	EC50	400	nM	CHEMBL4855006
6.40	EC50	400	nM	CHEMBL4864992
6.31	EC50	490	nM	CHEMBL3577169
6.31	EC50	489.8	nM	CHEMBL3577169
6.30	EC50	500	nM	CHEMBL4854909
6.30	EC50	500	nM	CHEMBL4878165
6.30	EC50	500	nM	CHEMBL4860146
6.30	EC50	500	nM	CHEMBL4852656
6.30	EC50	500	nM	CHEMBL4868780
6.30	EC50	500	nM	CHEMBL4859150
6.30	EC50	500	nM	CHEMBL4854655
6.30	EC50	500	nM	CHEMBL4851095
6.29	EC50	510	nM	CHEMBL3577170
6.29	EC50	512.9	nM	CHEMBL3577170
6.28	EC50	520	nM	CHEMBL1742484
6.28	EC50	524.8	nM	CHEMBL1742484

PubChem BioAssay actives

54 with measured affinity, of 80 total; 27 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(3-undecoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0180	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(3-pentadecoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0250	uM
(2S,3S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(3-undecoxyphenyl)propanoylamino]propoxy]phosphoryl]oxybutanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0309	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(2-pentadecoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0330	uM
(2S,3S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(3-undecoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxybutanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0398	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(2-undecoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0437	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[[(Z)-octadec-9-enoyl]amino]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0630	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(4-undecoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0759	uM
(2S)-2-amino-3-[[(2R)-3-[3-(3-heptoxyphenyl)propanoyloxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0813	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(4-pentadecoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.0851	uM
(2S)-2-amino-3-[[(2R)-3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.2884	uM
(2S)-2-amino-3-[[(2R)-3-[3-(4-heptoxyphenyl)propanoyloxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.4898	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[3-(2-nonoxyphenyl)propanoyloxy]propoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.5100	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.5200	uM
(2S)-2-amino-3-[[(2R)-3-hexadecanoyloxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.5370	uM
(2S,3S)-2-amino-3-[[(2R)-3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxybutanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.5800	uM
(2S,3S)-2-amino-3-[[(2R)-3-[3-(3-heptoxyphenyl)propanoyloxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxybutanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.7200	uM
(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-tetradecanoyloxypropoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.7700	uM
(2S,3S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxybutanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.8300	uM
(2S)-2-amino-3-[[(2R)-2-fluoro-3-[3-(2-undecoxyphenyl)propanoyloxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	0.8900	uM
(2S,3S)-2-amino-3-[[(2R)-3-hexadecanoyloxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxybutanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	1.0471	uM
[(2R)-3-[[(2S)-2-amino-3-methoxy-3-oxopropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (Z)-octadec-9-enoate	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	1.0965	uM
(2S)-2-amino-3-[[(2R)-3-[3-(2-heptoxyphenyl)propanoyloxy]-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	1.3490	uM
(2S,3S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-tetradecanoyloxypropoxy]phosphoryl]oxybutanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	1.5488	uM
(2S)-2-amino-3-[[(2R)-3-dodecanoyloxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	1.7783	uM
(2S)-2-amino-3-[hydroxy-[(2S)-2-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	1.9000	uM
(2S)-2-amino-3-[[(2R)-2-fluoro-3-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid	1226969: Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	ec50	1.9953	uM

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, decreases methylation	2
triphenyl phosphate	affects expression	1
quercitrin	increases expression	1
CGP 52608	affects binding, increases reaction	1
(+)-JQ1 compound	decreases expression	1
Arsenic Trioxide	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Particulate Matter	increases expression, increases abundance	1

ChEMBL screening assays

39 unique, capped per target: 35 functional, 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3579721	Binding	Agonist activity at GPR174 (unknown origin) transfected in HEK293FT cells after 1 hr by TGFalpha shedding assay	Structure-activity relationships of lysophosphatidylserine analogs as agonists of G-protein-coupled receptors GPR34, P2Y10, and GPR174. — J Med Chem
CHEMBL4807192	Functional	Inverse agonist activity at human GPR174 expressed in cells assessed as inhibition of CRE-luc reporter activity by measuring decrease in Gs-protein signalling activity relative to control	Inhibitors of GPR174 and Uses Thereof

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.